Eli Lilly's links to Purdue University go back a long way, and have been reinvigorated with $92.5 million in additional funding and renewed research collaborations.
Shares in French biotech Inventiva were on the slide this morning after AbbVie revealed that it had decided to abandon development of cedirogant, their drug candidate for autoimmune disease
